zapnometinib's mode of action with dual benefit

DGAP-News: Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Retrieved on: 
Thursday, December 2, 2021
Patient, Gesellschaft mit beschränkter Haftung, CEO, Orthohantavirus, Safety, CSO, Cell, Pharming, CMC, KU Leuven, Company, Viral load, MEK, Severe acute respiratory syndrome coronavirus 2, Gene expression, The Nomad Soul, Cytoplasm, COVID-19, History, Orthornavirae, Patent, RNP, RNA, Macrophage inflammatory protein, RSV, III, Therapy, Degenerative disease, Medicinal chemistry, Pharmaceutical industry, Vaccine, zapnometinib's mode of action with dual benefit, Atriva Therapeutics GmbH, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL BENEFIT, ATRIVA THERAPEUTICS GMBH

Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva's advisory board, bringing vast experience in late-stage pharmaceutical development

Key Points: 
  • Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva's advisory board, bringing vast experience in late-stage pharmaceutical development
    Frans van Dalen, Pharm D., representative of Atriva's lead investor Meneldor, continues support for Atriva on the scientific board
    Tbingen and Frankfurt, Germany, December 02, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes in its advisory board and its scientific board: Effective December 1, Piet Wigerinck, Ph.D., former Chief Scientific Officer (CSO) of the Belgian biotech company Galapagos, will join Atriva's advisory board on behalf of lead investor Meneldor.
  • D., founding partner and representative of Meneldor in Atriva's advisory board until now, will take a seat on the scientific board to continue his support for Atriva.
  • Paul Lelieveld, Ir., founding partner of Meneldor, said: "We warmly welcome Piet as a representative of Meneldor on the advisory board of Atriva.
  • Dr. Piet Wigerinck said: "I am very pleased to join the Atriva Therapeutics board at an exciting moment in its history.

DGAP-News: Atriva Therapeutics' lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

Retrieved on: 
Tuesday, November 9, 2021
Safety, MEK, Manuscript, Therapy, III, CRO, Macrophage inflammatory protein, Clinical trial, Gesellschaft mit beschränkter Haftung, RNA, Drug nomenclature, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, CSO, RSV, COVID-19, Orthohantavirus, Gene expression, Vaccine, Company, Antibody, Laboratory, Virus, Cytoplasm, RNP, Patent, Cell, Patient, Orthornavirae, Viral load, Transfusion-related acute lung injury, Pharmaceutical industry, zapnometinib's mode of action with dual benefit, Atriva Therapeutics GmbH, Viroclinics-DDL, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL BENEFIT, ATRIVA THERAPEUTICS GMBH, VIROCLINICS-DDL

Tbingen and Frankfurt, Germany, November 09, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced new results on the efficacy of Atriva's lead candidate zapnometinib against coronaviruses.

Key Points: 
  • Tbingen and Frankfurt, Germany, November 09, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced new results on the efficacy of Atriva's lead candidate zapnometinib against coronaviruses.
  • The preclinical study investigated the antiviral efficacy of zapnometinib against SARS-CoV-2 compared to drug-free controls in a well-established preclinical infection model based on Syrian hamsters.
  • The cell culture-based assays demonstrated that zapnometinib successfully inhibited viral replication by more than 90 % in all viruses tested.
  • The Atriva lead product zapnometinib (pINN, currently known as ATR-002) is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses.